Cash, cash equivalents and investments were $343.0M as of March 31, compared to $198.2M as of December 31, 2024. The company believes that its current cash, cash equivalents and investments will be sufficient to fund its planned clinical trials and regulatory activities, as well as support corporate operations, into 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics, Inc. (MLYS) Q1 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- Mineralys Therapeutics’ lorundrostat shows efficacy in NEJM-published study
- Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential
- Mineralys Therapeutics price target raised to $42 from $30 at H.C. Wainwright